4

Sheet

of

2

PTO/SB/98A (10:98)
Approved for use through 10/31/99. OM8 0551-0931
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

USAV2003/0020 - US - PCT

Unider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete if Known		
NEODIATION DIOCI COURT	Application Number	10/596,815	
INFORMATION DISCLOSURE	Filing Date	06-26-2006	
STATEMENT BY APPLICANT	First Named Inventor	SALTZMAN	
	Group Art Unit	1645	
(use as many sheets as necessary)	Examiner Name	N. Archie	

Attorney Docket Number

U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.1	U.S. Patent I Number	Kind Code ² (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Referent Payinges or Relevant		
/N.A./		2003/224511	(a somer)	Kenneth	12-04-2003	Figures Appear		

		ļ						
				ļ				
		 			+			
					 			
					1	***************************************		

					EIGN PATENT DOCUMEN	13		
Examiner Initials*	No.1	Office	Foreign Patent Do Number ⁴	Gurnent Kind Code ^s (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columne, Lines Where Relevant Passages or Relevant Figures Appear	T
/N.A	7	EP	1336847		Biofrontera Pharma	08-20-2003		Т
/N.A./		wo	02/055726		General Hospital Corp.	07-18-2002		T
/N.A./		WO	03/026403		Deltagen	04-03-2003		I
								I
								4
		-						4-
		_				-		+-
		-						+
		-				-		4-

Examiner Signature	/Nina Archie/	Date Considered	06/30/2008	-
 		}		,

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-latter code (WIPC Standard ST.3): ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 8 possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449B/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/596,815	
INF	DRMATI	ONL	ISCLOSURE	Filing Date	06-26-2006	
STATEMENT BY APPLICANT				First Named Inventor	SALTZMAN	
				Group Art Unit	1645	
(use as many sheets as necessary)				Examiner Name	N. Archie	
Sheet	2	of	2	Attorney Docket Number	USAV2003/0020 - US - PCT	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	,
xaminer stiais	or Cike Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the No.1 term (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue muniter(publisher, dily and/or country where publisher.		T
/N.A.		GUNCAR et al., Clystal structur of cathepsin N. A flip-flop of the ring of His23 allows carboxy-monoseptidase and carboxy-dipeptidase activity of the protease, Structure, Vol. 8, No. 3, March 15, 2000, pp. 305-313	
I		KLEMENCIC et al., Blochemical characterization of human cathepsin X revealed that the enzyme is an exceptibilities, acting as carboxymonopeptidase or carboxydipeptidase, Eur. J. Biochem., Vol. 287, 2000, pp. 5404-5412	
		LENNON-DUMENIIL et al., Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents dring dendritic cell actiation, Journal of Experimental Medicine, Vol. 198, No. 4, Aug.19, 2002, pp. 529-539	
		NAGLER et al., Human Cathepsin X. A Cysteine Protease With Unkque Carboxypeptidase Activity. Blochemistry, Vol. 36, 1999, pp. 12649-12654	-
		NAGLER et al., Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insertions, FEBS Latters, Vol. 434, 1996, pp. 135-139	
		RIESE et al., Cathepsins and comparimentalization in antigen presentation, Curr. Op. Immun, Vol. 12, 2000, pp. 107-113	
		SANTAMARIA et al., Cathepsin Z., a rovel human cysteine proteinase with a short propeptide domain and a unique chromosomal location, Journal of Biological Chemistry, Am. Soc. of Bio. Chemists, Vol. 273, No. 27, July 3, 1998, pp. 18918-16823	
$\sqrt{}$		TROMBETTA et al., Activation of lyeosomal function during dendrific cell maturation, Science, Vol. 299, No. 5811, Feb. 28, 2003, pp. 1400-1403	
			-

- 2				
1	Examiner		Date	00/00/0000
ı	Signature	/Nina Archie/	Considered	06/30/2008

*EXAMINER: littled if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the inclinidad case. Any comments on the amount of time you are required to complete his form should be sent to the Child Information Officiar. Platent and Tradement Officia, Washington, DC 20231. DO NOT SIRNO FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Peters, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.